A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284. Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More
Lantern Pharma has entered a strategic AI-driven collaboration with French biotechnology company Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI)1 inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its RADR AI platform to uncover biomarkers and… Read More
Lantern Pharma, an AI company developing targeted and transformative cancer therapies, has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumours and central nervous system (CNS) cancers. The… Read More
